| Ms Danielle N Zachary, CNS | |
|
609 W Memorial Rd, Oklahoma City, OK 73114-2006 | |
| (405) 418-5400 | |
| (405) 418-5401 |
| Full Name | Ms Danielle N Zachary |
|---|---|
| Gender | Female |
| Speciality | Certified Clinical Nurse Specialist (cns) |
| Experience | 16 Years |
| Location | 609 W Memorial Rd, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316171655 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | R 80480 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ssm Health St Anthony Hospital - Oklahoma City | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Medical Group, Llc | 7012914898 | 298 |
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease, today announced the pricing of its initial public offering of 1,925,000 units at $6.50 per unit (before underwriting discounts and commissions).
A team of researchers led by Janet Stanford, Ph.D., of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production - both of which impact immune function - increase the risk of developing prostate cancer.
Geisinger Health System's Genomic Medicine Institute has been approved to receive a $1.4 million research award from the Patient-Centered Outcomes Research Institute (PCORI) to study how best to share genomic lab results with patients.
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
› Verified 2 days ago
| Entity Name | Saint Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437195922 PECOS PAC ID: 7012914898 Enrollment ID: O20061109000189 |
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease, today announced the pricing of its initial public offering of 1,925,000 units at $6.50 per unit (before underwriting discounts and commissions).
A team of researchers led by Janet Stanford, Ph.D., of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production - both of which impact immune function - increase the risk of developing prostate cancer.
Geisinger Health System's Genomic Medicine Institute has been approved to receive a $1.4 million research award from the Patient-Centered Outcomes Research Institute (PCORI) to study how best to share genomic lab results with patients.
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
› Verified 2 days ago
| Entity Name | Crossway Medical Clinic W Memorial Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659780526 PECOS PAC ID: 9739403916 Enrollment ID: O20150116000459 |
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease, today announced the pricing of its initial public offering of 1,925,000 units at $6.50 per unit (before underwriting discounts and commissions).
A team of researchers led by Janet Stanford, Ph.D., of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production - both of which impact immune function - increase the risk of developing prostate cancer.
Geisinger Health System's Genomic Medicine Institute has been approved to receive a $1.4 million research award from the Patient-Centered Outcomes Research Institute (PCORI) to study how best to share genomic lab results with patients.
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Danielle N Zachary, CNS 609 W Memorial Rd, Oklahoma City, OK 73114-2006 Ph: (405) 418-5400 | Ms Danielle N Zachary, CNS 609 W Memorial Rd, Oklahoma City, OK 73114-2006 Ph: (405) 418-5400 |
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease, today announced the pricing of its initial public offering of 1,925,000 units at $6.50 per unit (before underwriting discounts and commissions).
A team of researchers led by Janet Stanford, Ph.D., of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production - both of which impact immune function - increase the risk of developing prostate cancer.
Geisinger Health System's Genomic Medicine Institute has been approved to receive a $1.4 million research award from the Patient-Centered Outcomes Research Institute (PCORI) to study how best to share genomic lab results with patients.
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
› Verified 2 days ago
Jamie Louise Hunt, APRN-CNS Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 800 Stanton L Young, Andrews Academic Tower, Suite 8400, Oklahoma City, OK 73104 Phone: 405-271-6173 Fax: 405-271-5892 | |
Mrs. Janet Elizabeth Kristic, APRN CLINICAL NURSE Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1117 Nw 50th, Oklahoma City, OK 73118 Phone: 405-842-4435 Fax: 405-842-2846 | |
Todd J Ramer, CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 4300 W Memorial Rd, Oklahoma City, OK 73120 Phone: 405-752-3539 | |
Andrea Jeanne Mccoy, R.N. Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 4050 W Memorial Rd, Oklahoma City, OK 73120 Phone: 405-608-3800 Fax: 405-608-3838 | |
Shanelle Stensaas, APRN-CNS Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 3300 Nw Expressway, Oklahoma City, OK 73112 Phone: 405-613-3351 | |
Leighann Fullagar, APRN-CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 3300 Nw Expressway, Oklahoma City, OK 73112 Phone: 405-713-7403 Fax: 405-713-2794 | |
Michelle Tull, ACNS-BC Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 800 Ne 10th St, Oklahoma City, OK 73104 Phone: 405-271-3402 |